EMA/182153/2014

European Medicines Agency decision

P/0094/2014

of 7 April 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311) (EMEA-001314-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0094/2014

of 7 April 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311) (EMEA-001314-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by APEIRON Biologics AG on 5 August 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 March 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311), solution for infusion, concentrate for solution for infusion, powder and solvent for solution for injection, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311), solution for infusion, concentrate for solution for infusion, powder and solvent for solution for injection, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311), solution for infusion, concentrate for solution for infusion, powder and solvent for solution for injection, powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to APEIRON Biologics AG, Campus-Vienna-Biocenter 5, 1030 - Vienna, Austria.

Done at London, 7 April 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/14201/2014 Corr

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001314-PIP01-12

Scope of the application

Active substance(s):

Chimeric anti-disialoganglioside (GD2) monoclonal antibody (ch14.18/CHO) (APN311)

Condition(s):

Treatment of neuroblastoma

Pharmaceutical form(s):

Solution for infusion

Concentrate for solution for infusion

Powder and solvent for solution for injection

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

APEIRON Biologics AG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, APEIRON Biologics AG submitted for agreement to the European Medicines Agency on 5 August 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 21 January 2014.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 21 March 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of neuroblastoma

The waiver applies to:

- the paediatric population from birth to less than 28 days;
- for solution for infusion, concentrate for solution for infusion, powder and solvent for solution for injection, powder for solution for infusion; for intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: treatment of neuroblastoma

2.1.1. Indication(s) targeted by the PIP

Treatment of neuroblastoma in minimal residual disease in patients from 1 month of age onwards in combination with aldesleukin and isotretinoin by means of a pain-minimising ch14.18/CHO (APN311) administration schedule

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 month to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for infusion for intravenous use

Concentrate for solution for infusion

Powder and solvent for solution for injection for intravenous use

Powder for solution for infusion for intravenous use

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	0	Not applicable
Non-clinical studies	1	**Study 1:** Repeat-dose juvenile toxicity study

Area	Number of studies	Description
Clinical studies	3	**Study 2:** Open-label, multi-centre, multiple-dose, single-arm trial to evaluate safety, toxicity and activity of APN311 in combination with aldesleukin in children from 1 month to less than 18 years of age (and young adults) with a neuroblastoma that is refractory to standard treatment or that has relapsed after high-dose therapy with allogeneic haploidentical stem cell transplantation **Study 3:** Open-label, multi-centre, dose-escalating/dose schedule-varying trial to evaluate pharmacokinetics, pharmacodynamics, safety, toxicity and activity of APN311 in combination with aldesleukin and isotretinoin in children from 1 year to less than 18 years of age (and young adults) with a neuroblastoma after at least one high-dose therapy with stem cell rescue **Study 4:** Open-label, multi-centre trial to evaluate pharmacokinetics, pharmacodynamics, safety, toxicity and activity of APN311 in children from 1 month to less than 18 years of age (and young adults) with a neuroblastoma that is refractory to standard therapy or that has relapsed or with a neuroblastoma that is refractory to or that has relapsed after at least one high-dose therapy with stem cell rescue

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2016
Deferral for one or more measures contained in the paediatric investigation plan:	Yes